Key Developments: Neurocrine Biosciences Inc (NBIX.O)

NBIX.O on Nasdaq

13.45USD
17 Apr 2014
Price Change (% chg)

$-0.39 (-2.82%)
Prev Close
$13.84
Open
$13.75
Day's High
$13.96
Day's Low
$13.35
Volume
485,552
Avg. Vol
1,062,952
52-wk High
$20.29
52-wk Low
$8.57

Search Stocks

Latest Key Developments (Source: Significant Developments)

Neurocrine Biosciences Inc announces issue of shares - Form 8-K
Thursday, 27 Feb 2014 04:38pm EST 

Neurocrine Biosciences Inc:Entered into an underwriting agreement with Jefferies LLC and J.P. Morgan Securities LLC relating to the issuance and sale of 8,000,000 shares at par value $0.001 per share.Says the price to the public in this offering is $17.75 per share.Says the net proceeds from this offering are expected to be about $133.1 mln.Says the offering is expected to close on or about Mar. 4.  Full Article

Neurocrine Biosciences Inc prices public offering of common stock
Wednesday, 26 Feb 2014 09:00pm EST 

Neurocrine Biosciences Inc:Announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share.Says gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be about $142 million.The offering is expected to close on or about March. 4, 2014.Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.  Full Article

Neurocrine Biosciences Inc announces proposed public offering of common stock
Tuesday, 25 Feb 2014 04:00pm EST 

Neurocrine Biosciences Inc:Says it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering.Says it will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock.Says Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering.  Full Article

Neurocrine Biosciences Inc issues FY 2014 earnings guidance below analysts' estimates
Thursday, 6 Feb 2014 11:01am EST 

Neurocrine Biosciences Inc:Expects FY 2014 net loss to be $56 mln to $61 mln, or $0.82 to $0.90 loss per share based on 68 million basic shares outstanding.FY 2014 net income of $(27.3) mln and EPS of $(0.37) - Thomson Reuters I/B/E/S.  Full Article

Neurocrine Biosciences Inc Raises FY 2013 Earnings Guidance
Tuesday, 29 Oct 2013 04:01pm EDT 

Neurocrine Biosciences Inc announced that for fiscal 2013, it expects net loss to be approximately $46 to $47 million, or approximately $0.70 loss per share based on 67 million basic common shares outstanding. The previous financial guidance for fiscal 2013 was a net loss of $50 to $55 million with year-end cash, investments and receivables exceeding $130 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report net loss of $51.8 million for fiscal 2013.  Full Article

Neurocrine Biosciences Inc Reaffirms FY 2013 Net Loss Guidance; Lowers FY 2013 Revenue Guidance-Conference Call
Thursday, 25 Jul 2013 05:00pm EDT 

Neurocrine Biosciences Inc announced that it expect its net loss for fiscal to approximate $50 million to $55 million and revenue for fiscal 2013 to be $2.9 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report net loss of $51 million and revenue of $3.1 million for fiscal 2013.  Full Article

Neurocrine Biosciences Inc Reaffirms FY 2013 Guidance-Conference Call
Thursday, 2 May 2013 09:00pm EDT 

Neurocrine Biosciences Inc announced that financial guidance for fiscal 2013 remains unchanged and expects approximately $3 million of revenue and net loss to be $50 million to $55 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $3.07 million and net income of $(52) million for fiscal 2013.  Full Article

Neurocrine Biosciences Inc Announces Start of Phase IIb Study of Elagolix in Uterine Fibroids
Wednesday, 27 Mar 2013 07:00am EDT 

Neurocrine Biosciences Inc announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, in development by AbbVie for the treatment of uterine fibroids and endometriosis. Neurocrine and AbbVie entered into a collaboration and license agreement for elagolix during 2010. The Phase IIb uterine fibroids study is a randomized, parallel, double-blind, placebo-controlled clinical trial evaluating elagolix in women with heavy uterine bleeding associated with uterine fibroids. This study will evaluate 280 subjects over a six-month placebo-controlled dosing period. The primary efficacy endpoint of the study is an assessment of the change in menstrual blood loss utilizing the alkaline hematin method comparing baseline to month six. Additional secondary efficacy endpoints will be evaluated including assessing the change in fibroid volume and hemoglobin. Bone mineral density will be assessed via DXA scan at baseline, the conclusion of dosing, and six months post-dosing.  Full Article

Neurocrine Biosciences Inc Issues FY 2013 Guidance
Friday, 8 Feb 2013 07:00am EST 

Neurocrine Biosciences Inc announced that for fiscal 2013, it expects revenue to approximate $3 million which consists solely of the amortization of up-front license fees and net loss to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding.  Full Article

Neurocrine Biosciences Inc Announces Start Of Second Phase IIb Study Of VMAT2 Inhibitor Nbi-98854 For Treatment Of Tardive Dyskinesia
Tuesday, 18 Dec 2012 04:12pm EST 

Neurocrine Biosciences Inc announced that it has initiated a Phase IIb clinical trial (Kinect 2 Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this six-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled, dose titration trial of 90 subjects with moderate to severe tardive dyskinesia and underlying mood disorders, gastrointestinal disorders, and schizophrenia or schizoaffective disorder. Topline data is expected in mid-2013. The Kinect 2 Study is a randomized, parallel, double-blind, placebo-controlled, dose titration Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with an underlying mood disorder (e.g., bipolar disorder), schizophrenia or schizoaffective disorder, or a gastrointestinal disorder with exposure to metoclopramide. This 90 subject study will assess once-daily NBI-98854 over a six-week placebo-controlled dosing period. Half of the randomized subjects will receive placebo and half will receive NBI-98854. The NBI-98854 dosing regimen will begin with a once-daily dose of 25mg for the initial two weeks. At the completion of the initial two weeks of dosing, based on certain efficacy and safety criteria, patients may be titrated to a once-daily 50mg dose, or continue on the once-daily 25mg dose for the following two-week period.  Full Article

Neurocrine's movement disorder drug meets main goal in mid-stage study

- Neurocrine Biosciences Inc said its movement disorder drug showed a reduction in symptoms compared to a placebo in a mid-stage study, sending its shares up 56 percent after the bell.

Search Stocks